Nuvectis Pharma annual cash and equivalents
2021
2022
2023
2024
2025
Nuvectis Pharma Cash & Equivalents Growth & History (NVCT)
Nuvectis Pharma's cash and equivalents was $31.6M for fiscal 2025.
View full Nuvectis Pharma company overviewNuvectis Pharma annual cash and equivalents history
| Fiscal year | Period ended | Cash and equivalents | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $31.6M | $13.1M | +70.69% |
| 2024 | 2024-12-31 | $18.5M | −$593,000 | −3.10% |
| 2023 | 2023-12-31 | $19.1M | −$867,000 | −4.34% |
| 2022 | 2022-12-31 | $20.0M | $14.3M | +248.19% |
| 2021 | 2021-12-31 | $5.7M | — | — |
Nuvectis Pharma quarterly cash and equivalents
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Cash and equivalents | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $22.2M | −$4.6M | −17.29% |
| Q1 2026 | 2026-03-31 | $25.1M | −$4.7M | −15.85% |
| Q4 2025 | 2025-12-31 | $31.6M | $13.1M | +70.69% |
| Q3 2025 | 2025-09-30 | $35.4M | $18.3M | +106.43% |
| Q2 2025 | 2025-06-30 | $26.8M | $8.7M | +47.90% |
| Q1 2025 | 2025-03-31 | $29.9M | $10.4M | +53.43% |
| Q4 2024 | 2024-12-31 | $18.5M | −$593,000 | −3.10% |
| Q3 2024 | 2024-09-30 | $17.2M | −$4.9M | −22.17% |
| Q2 2024 | 2024-06-30 | $18.1M | −$6.5M | −26.36% |
| Q1 2024 | 2024-03-31 | $19.5M | $4.0M | +25.83% |
| Q4 2023 | 2023-12-31 | $19.1M | −$867,000 | −4.34% |
| Q3 2023 | 2023-09-30 | $22.1M | −$1.6M | −6.69% |
| Q2 2023 | 2023-06-30 | $24.6M | $11.0M | +81.26% |
| Q1 2023 | 2023-03-31 | $15.5M | −$1.2M | −7.34% |
| Q4 2022 | 2022-12-31 | $20.0M | $14.3M | +248.19% |
| Q3 2022 | 2022-09-30 | $23.6M | — | — |
| Q2 2022 | 2022-06-30 | $13.6M | — | — |
| Q1 2022 | 2022-03-31 | $16.7M | — | — |
| Q4 2021 | 2021-12-31 | $5.7M | — | — |
Nuvectis Pharma cash and equivalents trends
Between the periods ended 2021-12-31 and 2025-12-31, Nuvectis Pharma's cash and equivalents increased from $5.7M to $31.6M, a change of $25.9M. The latest reported quarter, Q2 2026, shows $22.2M.
About the metric
What cash and equivalents mean
Cash and cash equivalents, often described as cash on hand, are highly liquid resources available for near-term obligations, investment, acquisitions, debt repayment, dividends, or share repurchases. This measure does not include short-term investments reported separately.
Calculation and source
Reported cash and equivalents
TickerStat standardizes cash and cash equivalents reported on the balance sheet. Restricted cash is included only when the company reports it within the selected consolidated cash concept. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Nuvectis Pharma source filings ↗Community posts
Nuvectis’ partner reports expanded glioma responses for experimental BRAF inhibitor
Nuvectis ($NVCT) reported expanded Phase 1b results for NXP200 from partner Haisco’s Chinese study in recurrent or progressive BRAF V600-mutated glioma. Tumor responses occurred in eight of twenty evaluable patients with high-grade disease ...
